Complement as a target in COVID-19?
Top Cited Papers
- 23 April 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 20 (6), 343-344
- https://doi.org/10.1038/s41577-020-0320-7
Abstract
There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. This Comment article from Lambris and colleagues considers the therapeutic potential of targeting the complement system in patients with COVID-19.Keywords
This publication has 9 references indexed in Scilit:
- Predicting Hospital Utilization and Inpatient Mortality of Patients Tested for COVID-19medRxiv, 2020
- Clinical Characteristics of Covid-19 in ChinaNew England Journal of Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activationmedRxiv, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Clinical promise of next-generation complement therapeuticsNature Reviews Drug Discovery, 2019
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus PathogenesismBio, 2018
- Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndromeCritical Care Medicine, 1992